Nykode Therapeutics AS (FRA:5VB) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jun. 28, 2026)


FRA:5VB Nykode Therapeutics AS FRA:5VB
37 GF Score
Price €0.25
GF Value €0.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Float Percentage Of Total Shares Outstanding?

Nykode Therapeutics AS FRA:5VB -0.61% 37 Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 28, 2026. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nykode Therapeutics AS's float shares is 0.00 Mil. Nykode Therapeutics AS's total shares outstanding is 326.55 Mil. Nykode Therapeutics AS's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nykode Therapeutics AS's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nykode Therapeutics AS's Institutional Ownership is 11.54%.

FRA:5VB
37GF Score
Nykode Therapeutics AS FRA:5VB
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nykode Therapeutics AS's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/326.55
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Nykode Therapeutics AS (FRA:5VB) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Float Percentage Of Total Shares Outstanding too high?
Nykode Therapeutics AS's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Nykode Therapeutics AS's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for FRA:5VB:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for FRA:5VB

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.49
GF Value